Corteva, Inc. (CTVA): what the price requires
At today's price, Corteva, Inc. (CTVA) is priced for +12.5% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/CTVA
Headline
| Field | Value |
|---|---|
| Ticker | CTVA |
| Company | Corteva, Inc. |
| Current price | $85.84/sh |
| Composition | Seed 57% / Crop Protection 43% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 13.6% |
| Operating margin today | 16.7% |
| Margin compression implied | -3.1pp |
| Implied growth | 12.5% |
| Multiple paid | 19x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 8.9% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.8pp.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | +1.88σ |
| cohort percentile (of 76 peers) | 54 |
| sustained it ~5 years at this level | 49% |
| implied end-window share | 0% |
Valuation X-Ray
Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 3.23x | 4 | expensive |
| Earnings | 2.82x | 2 | expensive |
| Relative | 1.98x | 3 | expensive |
| Growth | 1.24x | 3 | expensive |
Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.
Per-Model Detail (n=12)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $67.06 | 1.28x | yes | FCF base $2.1B, growth 7% (input: historical growth), terminal g 4.0%, WACC 9.1%, 6yr projection |
| DCF Exit Multiple | Growth | $83.78 | 1.02x | yes | Exit EV/EBITDA: 94.2x / 96.2x / 98.2x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $43.42 | 1.98x | yes | P/E 22.41x (blended: static sector reference 18x + trailing (TTM) 33x), scenarios: 18.7x / 22.4x / 26.1x (bear / base = reference held flat / bull), EV/EBITDA 26.4x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $28.38 | 3.02x | yes | BV/sh $36.17, ROE (TTM) 7.3%, ke 9.3% |
| Two-Stage Excess Return | Asset | $25.00 | 3.43x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $69.31 | 1.24x | yes | Rev $17.9B, growth 7% (input: historical growth; tapered), Terminal P/S: 2.7x / 3.2x / 3.8x (bear / base = today's held flat / bull, cap 8x) |
| Growth-Adjusted P/E | Relative | — | — | no | — |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | $24.50 | 3.50x | yes | BV $36.17 + 5yr PV of (ROE (TTM) 7.3% − Kₑ 9.3%) × BV; BV grows 4.7%/yr |
| Graham Number | Asset | $46.01 | 1.87x | yes | √(22.5 × EPS $2.60 × BVPS $36.17) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $11.08 | 7.75x | yes | EBITDA $0.60B × sector EV/EBITDA 12.0x |
| FCF Yield | Earnings | $33.27 | 2.58x | yes | FCF $2046.0M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | $2.18 | 39.37x | yes | EPS $2.60 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median) |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $66.39 | 1.29x | yes | Revenue $17.89B × sector P/S 2.5x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | $28.12 | 3.05x | yes | EPS $2.60 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $499.0m |
| Net debt / NOPAT (after-tax) | 0.19x |
| Net debt / operating income (pre-tax) | 0.16x |
| Share count CAGR (buyback) | -2.0% |
| Burning cash | no |
Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.
Bullet Takeaways
The defining feature is the seed moat: Corteva runs a 17.2% operating margin on a portfolio anchored by thousands of germplasm and biotechnology patents, and only the growth-DCF method reaches the price. The market is paying a durability premium the static frames cannot capture.
The transformational catalyst is the Q4 2026 separation into two companies, a high-margin seed business named Vylor and a standalone crop-protection company. The split is the explicit attempt to surface the value SOTP analysis says is trapped in the combined structure.
Q1 2026 was strong: net sales up 11% to $4.90 billion, operating EBITDA up 21%, and both Seed and Crop Protection growing double digits with 240 basis points of margin expansion. Net debt of about $499 million is negligible against $3.1 billion of operating income.
Bull Case
The structural advantage that defines Corteva is the seed franchise, and the margin and return data show it is real. The company breeds germplasm with advanced traits to produce high yield potential for farmers around the world, and pairs it with a crop-protection segment that defends those yields against weeds, insects, and disease (FY2025 10-K, accession 0001755672-26-000004). That combination earns a 17.2% operating margin on $3.1 billion of operating income, and the moat is patent-protected at scale: the seed business carries more than 4,000 germplasm patents and over 2,000 biotechnology patents, plus the largest global seed production network. Most corn hybrids and soybean varieties Corteva sells contain biotechnology traits, many licensed under long-term agreements (FY2025 10-K, accession 0001755672-26-000004). A farmer choosing seed for a once-a-year planting decision does not switch on price; he switches on yield, and yield is exactly what the patent library protects.
The operating momentum confirms the franchise is healthy. Q1 2026 net sales rose 11% to $4.90 billion with 7% organic growth, operating EBITDA climbed 21% to $1.44 billion, and operating EPS jumped 33% to $1.50, with both Seed and Crop Protection delivering double-digit EBITDA growth and 240 basis points of margin expansion. Management reaffirmed full-year guidance of $4.0 to $4.2 billion in operating EBITDA, noting the first half is running slightly ahead of plan. This is a business compounding earnings while expanding margins, which is why the growth-DCF method, the only family that reaches the price, is doing the work.
The catalyst that crystallizes the value is the planned separation. Corteva is on track to spin off its advanced seed and genetics business as a standalone company named Vylor in the fourth quarter of 2026, leaving a focused crop-protection company behind. The logic is that the market undervalues the combined entity: the seed business is higher-margin and more defensible than crop protection, and as separate companies each should earn a multiple appropriate to its profile rather than a blended one. The balance sheet supports the move, with net debt of just $499 million against $3.1 billion of operating income, and the company plans about $500 million of buybacks in the first half of 2026. The bull case is a patent-moated seed franchise, double-digit earnings growth, and a structural catalyst designed to release the value the static methods cannot see.
Bear Case
The fragility in Corteva is not leverage; it is the working-capital and cyclical structure of an agricultural-input business that the separation will expose in two halves. The company's own filing flags the seasonality of its business and the customer credit programs it runs, alongside exposure to financial-market disruption and interest-rate fluctuations (FY2025 10-K, accession 0001755672-26-000004). Ag inputs are sold on a tight annual calendar tied to planting seasons, and Corteva extends credit to dealers and farmers, which means a bad crop year, a commodity-price slump, or a stretch of weak farmer income can swing receivables, inventory, and demand sharply in the same direction. The earnings are steadier than a pure commodity producer's, but they are not the smooth recurring stream a 17% margin and a patent moat might suggest in isolation.
The separation itself introduces real, near-term fragility. Corteva estimates about $350 million of one-time separation costs plus roughly $100 million in net dis-synergies, and splitting a vertically integrated seed-and-chemistry business removes the cross-selling and shared-cost advantages that the combined structure provided. The standalone crop-protection company, New Corteva, is the weaker half: it faces cyclical demand and intensifying competition from generic off-patent chemistries, which compress pricing as products lose exclusivity. The crop-protection segment serves the global agricultural-input industry with products that protect against weeds, insects, pests, and disease (FY2025 10-K, accession 0001755672-26-000004), but that market is crowded with generic manufacturers once a molecule comes off patent. As a standalone, it may earn a lower multiple than it does today inside Corteva.
The valuation leaves little cushion for a disappointing split. Asset, earnings-power, and peer-multiple methods all say the stock is richly valued; only the growth-DCF reaches the price. If the spinoff fails to surface the expected value, if separation costs run high, if the crop-protection business trades poorly as a standalone, or if a weak ag cycle hits during the transition, the methods anchored to current earnings, not the optimistic SOTP, are the honest read. The bear case is that you are paying a separation-success premium for a seasonal, partly-cyclical business in the middle of a complex breakup.
Valuation
Invert the price first. At $78.57 the market pays about 17x company-wide operating income, which implies roughly 9.4% annual operating-profit growth over five years, computed at an 8.85% cost of capital with 4% terminal growth. That implied pace is within what Corteva has recently delivered, so the priced-in assumption reads as within range. The price also requires the operating margin to hold near 12.5% on the model's terms against the 17.2% trailing, so the math leans on durable but slightly-fading profitability. The read is rate-sensitive, with each one-point move in the cost of capital shifting the required growth by about 6.5 points.
The valuation families split in a telling way. Asset, earnings-power, and peer-multiple methods all say the stock is richly valued, and only the growth-DCF family reaches the price. That pattern is the signature of a quality compounder priced for a durability the static frames cannot capture, in this case the patent-protected seed moat. A standalone DCF on the combined business implies a value in the low-$50s, which is why the gap between the methods and the price is best understood as the value the market expects the Vylor separation to unlock.
The synthesis is that Corteva is priced as a sum-of-the-parts story. The combined-company methods near the $71 base, and the low-$50s DCF, say the stock is fully valued on its current structure. The bullish case, and the analyst targets near $89 to $95, rests on the seed business earning a premium standalone multiple as Vylor and the crop-protection business being valued separately. If the separation delivers, the high end near $101 becomes reachable; if it disappoints or the ag cycle softens during the transition, the base near $71 is the relevant anchor. This is a catalyst-driven valuation where the verdict turns on whether the Q4 2026 split surfaces the premium the seed franchise deserves.
Catalysts
The dominant catalyst is the planned separation. Corteva is on track to spin off its advanced seed and genetics business as a standalone company named Vylor in the fourth quarter of 2026, leaving a focused crop-protection company behind. Vylor will launch with more than 4,000 germplasm patents, over 2,000 biotechnology patents, the largest global seed production network, and leading positions in key row crops. The company estimates about $350 million of one-time separation costs plus roughly $100 million in net dis-synergies. Every milestone toward the Q4 close, the capital structure of each entity, and the multiples the two businesses command as standalones are catalysts in either direction, since the entire premium over the combined-company DCF rests on the split surfacing trapped value.
On fundamentals, Q1 2026 results reported in early May delivered net sales up 11% to $4.90 billion with 7% organic growth, operating EBITDA up 21% to $1.44 billion, and operating EPS up 33% to $1.50, with both Seed and Crop Protection growing double digits and expanding margins 240 basis points. Management reaffirmed full-year guidance of $4.0 to $4.2 billion in operating EBITDA and $3.45 to $3.70 in operating EPS, and plans about $500 million of buybacks in the first half. Analyst sentiment is firmly constructive, with a Buy consensus, targets ranging from about $77 to $100, and Morgan Stanley raising its target to $95 at Overweight. The next earnings report, the trajectory of farmer income and commodity prices, and progress on the Vylor separation are the events most likely to move the thesis.
Sources: Corteva Q1 2026 results (StockTitan), Corteva names seed spinoff Vylor (StockTitan), Corteva Vylor spinoff reframes valuation (Simply Wall St), Corteva Q1 2026 8-K (SEC).
Peer Cohorts (Per Segment, With Filing Citations)
Seed / Crop Protection (reported)
- FMC (FMC CORPORATION)
- (no filing in the citation store)
- MOS (MOSAIC CO)
- (no filing in the citation store)
- CF (CF INDUSTRIES HOLDINGS, INC.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.